A phase II trial of induction NAB-paclitaxel and cisplatin ...

https://www.researchgate.net/publication/316837767...

Request PDF | A phase II trial of induction NAB-paclitaxel and cisplatin followed by concurrent chemoradiotherapy in patients with locally advanced nasopharyngeal carcinoma | Objectives ...

Secondary resectability in locally advanced pancreatic ...

https://www.researchgate.net/publication/330095869...

Home; Endocrine Gland Neoplasms; Neoplasms

154361-50-9 | MFCD00930626 | 5'-Deoxy-5-fluoro-N ...

https://www.aablocks.com/prod/154361-50-9 -

Title: Phase II clinical trial of induction chemotherapy with fixed dose rate gemcitabine and cisplatin followed by concurrent chemoradiotherapy with capecitabine for locally advanced pancreatic cancer. Journal: Cancer chemotherapy and pharmacology 20120901

Offer Count: 4 Price Range: \$5 - \$35

www.science.gov

https://www.science.gov/topicpages/a/advanced+inoperable+squamous.html -

May 01, 2018 · Parenteral Nutrition for Patients Treated for Locally Advanced Inoperable Tumors of the Head and Neck. ClinicalTrials.gov. 2018-03-28. Squamous Cell Carcinoma of the Hypopharynx S

Search result for 'advanced dermal fillers'

https://www.dovepress.com/search_results.php?... •

Encouraging Pathological Complete Response Rate from Neoadjuvant Chemotherapy with Albumin-Bound Paclitaxel Plus Cisplatin and Capecitabine for Locally Advanced Esophageal Squamous Carcinoma: Preliminary Outcome of a Retrospective Study. Zhang W, Li Y, Xue L, Qu D, Jiang Z, Wang Z, Yang Z, Zhou A. Cancer Management and Research 2021, 13:2163-2170

clinicaltrials.gov

https://clinicaltrials.gov/ct2/results?displayxml=true&count=1000&start=54001

Recruiting Advanced Breast Carcinoma; Anatomic Stage III Breast Cancer AJCC v8; Anatomic Stage

Induction chemotherapy with albumin-bound paclitaxel plus lobap







AII Images Videos

1.620 Results Any time ▼

Liposome-paclitaxel and carboplatin combination ...

https://www.sciencedirect.com/science/article/pii/S127832182100024X

Jul 01, 2021 · Although the FP regimen is the standard regimen for CCRT for esophageal cancer, paclitaxel plus platinum agent has also been used as one of the main options for nearly a decade. In 2014, Tang et al. treated patients with locally advanced ESCC with 3-week schedule paclitaxel and cisplatin-based definitive CCRT . The results showed that the

Author: J. Zeng, X. Cui, L. Cheng, Y. Chen, X. ... Publish Year: 2021

Male: 72

multi-institutional randomized phase III study comparing ...

https://academic.oup.com/jjco/article/51/5/836/6174321 -

Mar 17, 2021 · A multi-institutional randomized phase III study comparing weekly carboplatin plus nabpaclitaxel and daily low-dose carboplatin as regimens for concurrent chemoradiotherapy in elderly patients with unresectable locally advanced non-small cell lung cancer: Japan Clinical Oncology Group

Author: Ryo Shimoyama, Shota Omori, Shog... Publish Year: 2021

Phase II study of neoadjuvant therapy with nab-paclitaxel ...

https://europepmc.org/article/MED/27244882 -


Aug 01, 2016 · Background We carried out a phase II study to evaluate the efficiency and safety of the combination of nanoparticle albumin bound-paclitaxel (nab-paclitaxel) and cisplatin as preoperative chemotherapy for locally advanced esophageal squamous cell carcinoma (ESCC)Results: From Oct 2011 to Dec 2012, 35 patients were enrolled and received neoadjuvant chemotherapy.

Cited by: 2 Author: Yun Fan, Youhua Jiang, Xinming Zhou, Qi.

Publish Year: 2016

The antitumor effect of lobaplatin against Ishikawa ... https://www.sciencedirect.com/science/article/pii/S0753332219301647

Jun 01, 2019 · The CCK-8 assay was used to evaluate anti-proliferative effect of lobaplatin on Ishikawa cells. After the treatment of Iobaplatin for 48 h, the proliferation of Ishikawa cells was markedly attenuated and represented a dose-dependent manner (Fig. 1A), the inhibition rates were $34.73 \pm 0.79\%$ and $56.3 \pm 0.63\%$ respectively at 2ug and 4ug/mL dosage, which led to a significant inhibition of .





Induction chemotherapy with albumin-bound paclitaxel plus lobap







ALL

IMAGES

VIDEOS

1,590 Results

Any time *

Phase II study of neoadjuvant therapy with nab-paclitaxel ... https://europepmc.org/article/MED/27244882 •

Aug 01, 2016 - Background We carried out a phase II study to evaluate the efficiency and safety of the combination of nanoparticle albumin bound-paclitaxel (nab-paclitaxel) and cisplatin as preoperative chemotherapy for locally advanced esophageal squamous cell carcinoma (ESCC)Results: From Oct 2011 to Dec 2012, 35 patients were enrolled and received neoadjuvant chemotherapy.

Cited by: 2 Author: Yun Fan, Youhua Jiang, Xinming Zhou, Qi...

Publish Year: 2016

Liposome-paclitaxel and carboplatin combination ...

https://www.sciencedirect.com/science/article/pii/S127832182100024X

Jul 01, 2021 - Although the FP regimen is the standard regimen for CCRT for esophageal cancer, paclitaxel plus platinum agent has also been used as one of the main options for nearly a decade. In 2014, Tang et al. treated patients with locally advanced ESCC with 3-week schedule paclitaxel and cisplatin-based definitive CCRT. The results showed that the ...

Author: J. Zeng, X. Cui, L. Cheng, Y. Chen, X. ... Publish Year: 2021

Male: 72

multi-institutional randomized phase III study comparing ...

https://academic.oup.com/jjco/article/51/5/836/6174321 -

Mar 17, 2021 · A multi-institutional randomized phase III study comparing weekly carboplatin **plus** nabpaclitaxel and daily low-dose carboplatin as regimens for concurrent chemoradiotherapy in elderly patients with unresectable locally advanced non-small cell lung cancer: Japan Clinical Oncology Group Study JCOG1914

Author: Ryo Shimoyama, Shota Omori, Shog... Publish Year: 2021

The antitumor effect of lobaplatin against Ishikawa ...

https://www.sciencedirect.com/science/article/pii/S0753332219301647

Jun 01, 2019 · The CCK-8 assay was used to evaluate anti-proliferative effect of lobaplatin on Ishikawa cells. After the treatment of lobaplatin for 48 h, the proliferation of Ishikawa cells was markedly attenuated and represented a dose-dependent manner (Fig. 1A). the inhibition rates were $34.73 \pm 0.79\%$ and $56.3 \pm 0.63\%$ respectively at 2ug and 4ug/mL dosage, which led to a significant inhibition of ...

Author: Jingchao He, Haijun Zhang Publish Year: 2019